CClinicalTrials.gg
CompletedNCT03175003Updated May 30, 2019

Assessment of a New Food Product in Metabolically at Risk Children

An interventional study of Food Product in Cardiovascular Risk Factor, Inflammation and Micronutrient Deficiency, sponsored by University of California, Davis. Completed at 1 site in United States. Open to participants aged 9 Years to 13 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-05-30.

Sponsored by University of California, Davis · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
68
Allocation
Randomized
Ages
9 Years to 13 Years
Sex
All
01

Study summary

The current study conducted will lend toward the optimization of the development of a food product that will promote a shift towards improved metabolic health. Specifically, this trial will determine the optimal level of protein needed to elicit positive changes in markers of inflammation, metabolic and micronutrient status, hepatic lipid metabolism, vascular function, and the relationship of these changes to the metabolome in school aged children (9 - 13 years of age).

Read the detailed description

Each participant will be asked to participate in a screening and 2 study intervention visits. Each intervention visit will include anthropometric measures, complete the education component, vascular function tests, and a blood draw and spot urine. The screening visit will confirm the child's eligibility for study enrollment and will serve to acclimate the child to the vascular function, and physical activity measurements. The remaining 2 visits will be scheduled 4 weeks apart. The participants will also be provided and asked to wear a physical activity monitor, which in addition to tracking physical activity, will also be used to incorporate a nutrition education program. The parent/guardian will be asked to help with providing the child the daily food product and to help their child fill out the compliance log. Volunteers will also be sought for stool and saliva collection.

02

Conditions studied

  • Cardiovascular Risk Factor
  • Inflammation
  • Micronutrient Deficiency

Browse trials for

03

In context

Inflammation

3,439 studies on the registry are indexed under Inflammation; 629 are open to participants now.

This study's enrollment of 68 is above the median of 50 across 2,436 interventional studies indexed under Inflammation.

Browse Inflammation studies →

Lead sponsor

University of California, Davis is the lead sponsor of 798 studies on the registry; 146 are open to participants now.

Of its 65 completed or terminated interventional studies of FDA-regulated products, 43 (66%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
9 Years to 13 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Male or Female 9-13 years old
  • Subject is willing and able to comply with the study protocols
  • Subject is willing to consume the test products
  • Access to a smart phone or tablet at least 1x / week; and willing to download a free applications associated with the study

Exclusion criteria

Exclusion Criteria:

  • Allergies or intolerances to peas, legumes, pulses, soy, dairy or wheat/gluten
  • Under current medical supervision
  • Tanner Score = 4
  • Non-English speaking
  • Current participation in a daily exercise routine of moderate or high intensity
  • Self-reported presence of disease, a history of serious illness, or who are currently under acute medical care.
  • Currently taking prescription drugs or supplements
  • Any supplement use, including multi-vitamin/ mineral, herbal, plant or botanical, fish oil, and oil supplements.
  • Self-reported malabsorption or gastrointestinal issues
  • Current enrollee in a clinical research study.
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
68 participants (actual)

Study arms

  • Active comparator
    Food Product 1

    Macronutrient similar to experimental, micronutrient lower than experimental

    Other: Food Product

  • Active comparator
    Food Product 2

    Macronutrient lower than experimental, micronutrient similar to experimental

    Other: Food Product

  • Experimental
    Food Product 3

    Experimental 1

    Other: Food Product

  • Experimental
    Food Product 4

    Experimental 2

    Other: Food Product

Interventions

  • OtherFood Product

    Each food product will provide similar calories, but a different micro- and macro-nutrient composition

06

What researchers measure

Primary outcomes

  1. Change in Microvascular Function

    Measured by EndoPAT2000. A PAT (Peripheral Arterial Tone) ratio is created using the post and pre occlusion values

    Time frame: Compare change in baseline and 4 weeks

Secondary outcomes

  1. Change in Metabolome

    Measured with Nuclear Magnetic Resonance (NMR)

    Time frame: Compare change in baseline and 4 weeks

  2. Change in Lipidome

    Measured by Ultra Performance Liquid Chromatography (UPLC) tandem mass-spectrometry

    Time frame: Compare change in baseline and 4 weeks

  3. Change in Inflammatory Markers

    Measured by immunoassay

    Time frame: Compare change in baseline and 4 weeks

07

Study locations

1 site
  • Department of Nutrition
    Davis, California 95616, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 30, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03175003
Lead sponsor
University of California, Davis
Responsible party
Sponsor
First posted
Jun 5, 2017
Start date
Jun 15, 2017
Primary completion
Mar 24, 2018
Completion
May 24, 2018
Last update
May 30, 2019

Study contacts

Carl L Keen, PhD
principal investigator · Principal Investigator

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion